Unknown

Dataset Information

0

Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice.


ABSTRACT: Multimodality therapies are used to manage patients with hepatocellular carcinoma (HCC), although advanced HCC is incurable. Oncolytic virus therapy is probably the next major breakthrough in cancer treatment. The third-generation oncolytic herpes simplex virus type 1 (HSV-1) T-01 kills tumor cells without damaging the surrounding normal tissues. Here we investigated the antitumor effects of T-01 on HCC and the host's immune response to HCC cells. The cytopathic activities of T-01 were tested in 14 human and 1 murine hepatoma cell line in vitro. In various mouse xenograft models, HuH-7, KYN-2, PLC/PRF/5 and HepG2 human cells and Hepa1-6 murine cells were used to investigate the in vivo efficacy of T-01. T-01 was cytotoxic to 13 cell lines (in vitro). In mouse xenograft models of subcutaneous, orthotopic and peritoneal tumor metastasis in athymic mice (BALB/c nu/nu), the growth of tumors formed by the human HCC cell lines and hepatoblastoma cell line was inhibited by T-01 compared with that of mock-inoculated tumors. In a bilateral Hepa1-6 subcutaneous tumor model in C57BL/6 mice, the growth of tumors inoculated with T-01 was inhibited, as was the case for contralateral tumors. T-01 also significantly reduced tumor growth. T-01 infection significantly enhanced antitumor efficacy via T cell-mediated immune responses. Results demonstrate that a third-generation oncolytic HSV-1 may serve as a novel treatment for patients with HCC.

SUBMITTER: Nakatake R 

PROVIDER: S-EPMC5834814 | biostudies-other | 2018 Mar

REPOSITORIES: biostudies-other

altmetric image

Publications

Third-generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice.

Nakatake Richi R   Kaibori Masaki M   Nakamura Yusuke Y   Tanaka Yoshito Y   Matushima Hideyuki H   Okumura Tadayoshi T   Murakami Takashi T   Ino Yasushi Y   Todo Tomoki T   Kon Masanori M  

Cancer science 20180214 3


Multimodality therapies are used to manage patients with hepatocellular carcinoma (HCC), although advanced HCC is incurable. Oncolytic virus therapy is probably the next major breakthrough in cancer treatment. The third-generation oncolytic herpes simplex virus type 1 (HSV-1) T-01 kills tumor cells without damaging the surrounding normal tissues. Here we investigated the antitumor effects of T-01 on HCC and the host's immune response to HCC cells. The cytopathic activities of T-01 were tested in  ...[more]

Similar Datasets

| S-EPMC9118137 | biostudies-literature
| S-EPMC4326267 | biostudies-literature
| S-EPMC6349778 | biostudies-literature
| S-EPMC5435599 | biostudies-literature
| S-EPMC4096170 | biostudies-literature
| S-EPMC8235327 | biostudies-literature
| S-EPMC2835221 | biostudies-other
| S-EPMC3907427 | biostudies-literature
| S-EPMC2871708 | biostudies-literature
| S-EPMC7105799 | biostudies-literature